171 related articles for article (PubMed ID: 22330069)
1. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
2. RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia.
Gu C; Feng M; Yin Z; Luo X; Yang J; Li Y; Li T; Wang R; Fei J
Oncotarget; 2016 Apr; 7(15):20561-73. PubMed ID: 26967392
[TBL] [Abstract][Full Text] [Related]
3. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
[TBL] [Abstract][Full Text] [Related]
4. Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
Nakamura S; Takemura T; Tan L; Nagata Y; Yokota D; Hirano I; Shigeno K; Shibata K; Fujie M; Fujisawa S; Ohnishi K
Carcinogenesis; 2011 Dec; 32(12):1758-72. PubMed ID: 21890458
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Sengupta A; Banerjee D; Chandra S; Banerjee S
J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K
Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726
[TBL] [Abstract][Full Text] [Related]
7. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
8. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Withey JM; Harvey AJ; Crompton MR
Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
[TBL] [Abstract][Full Text] [Related]
9. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
[TBL] [Abstract][Full Text] [Related]
10. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
11. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
[TBL] [Abstract][Full Text] [Related]
12. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
Bártová E; Harnicarová A; Pacherník J; Kozubek S
Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
[TBL] [Abstract][Full Text] [Related]
13. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Chu S; Li L; Singh H; Bhatia R
Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
[TBL] [Abstract][Full Text] [Related]
14. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
16. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
Wang W; Du Y; Li NN; Lv FF; Lin GQ
Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
18. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
19. Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells.
Potin S; Bertoglio J; Bréard J
FEBS Lett; 2007 Jan; 581(1):118-24. PubMed ID: 17182041
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Puccetti E; Güller S; Orleth A; Brüggenolte N; Hoelzer D; Ottmann OG; Ruthardt M
Cancer Res; 2000 Jul; 60(13):3409-13. PubMed ID: 10910048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]